Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Pipeline Insight and Therapeutic Assessment Reviewed in 2017
Market Research Hub (MRH) has recently added a new report to its vast online database. This research study is titled as Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Pipeline
(EMAILWIRE.COM, November 04, 2017 ) Market Research Hub (MRH) has recently added a new report to its vast online database. This research study is titled as “Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Pipeline” 2017 which presents an in-depth study about the production, consumption, market volume, revenue (million USD) and market share across different geographical regions.
Request For Free Sample - https://www.marketresearchhub.com/enquiry.php?type=S&repid=1361376
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Hormonal Disorders, Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders and Ophthalmology which include indications Acromegaly, Neuroendocrine Tumors, Chronic Pain, Diabetic Retinopathy, Neuropathic Pain, Pituitary ACTH Hypersecretion (Cushing Disease), Age Related Macular Degeneration, Gastric Motility Disorder, Gastrointestinal Tumor, Hypoglycemia, Medulloblastoma, Meningioma, Neuroblastoma, Pancreatic Tumor, Pituitary Tumor and Polycystic Kidney Disease.
Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics
Browse Full Report With TOC - https://www.marketresearchhub.com/report/somatostatin-receptor-type-2-srif1-or-sstr2-pipeline-review-h2-2017-report.html
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Companies Involved in Therapeutics Development
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Drug Profiles
AP-102-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR-Drug Profile
Product Description
Mechanism Of Action
Continue….
Enquire About this Report - https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1361376
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 800-998-4852 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: https://www.marketresearchhub.com/
Read More Related News: https://www.industrynewsanalysis.com/
Request For Free Sample - https://www.marketresearchhub.com/enquiry.php?type=S&repid=1361376
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Hormonal Disorders, Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders and Ophthalmology which include indications Acromegaly, Neuroendocrine Tumors, Chronic Pain, Diabetic Retinopathy, Neuropathic Pain, Pituitary ACTH Hypersecretion (Cushing Disease), Age Related Macular Degeneration, Gastric Motility Disorder, Gastrointestinal Tumor, Hypoglycemia, Medulloblastoma, Meningioma, Neuroblastoma, Pancreatic Tumor, Pituitary Tumor and Polycystic Kidney Disease.
Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics
Browse Full Report With TOC - https://www.marketresearchhub.com/report/somatostatin-receptor-type-2-srif1-or-sstr2-pipeline-review-h2-2017-report.html
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Companies Involved in Therapeutics Development
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2)-Drug Profiles
AP-102-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR-Drug Profile
Product Description
Mechanism Of Action
Continue….
Enquire About this Report - https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1361376
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 800-998-4852 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: https://www.marketresearchhub.com/
Read More Related News: https://www.industrynewsanalysis.com/
Contact Information:
Market Research Hub
Ashwani Kailiya
Tel: 5186212074
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Research Hub
Ashwani Kailiya
Tel: 5186212074
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results